Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is
evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or
no longer amenable to established therapies.